All the Active Ingredient Drugs
PARP Enzyme Inhibitor. Olaparib 100 mg, 150 mg. F.C. TABS.:56. 300 mg (2 tabs of 150mg ) taken twice dly., equiv. to a total dly. dose of 600 mg. The 100 mg tab. is available for dose reduct.
Ovar. cancer: Pts. should start tmt. with Lynparza no later than 8 wks. after complet. of their final dose of the platin.-contain. regimen. It is recommended that tmt., be cont. until progres. of the underl. dis. There are no data on retreat. with Lynparza follow. subseq. relapse.
Important differences in posology between Lynparza tabs. and caps.: Tabs. (100 mg /150 mg) should not be substit. for caps. (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailab.of each formul. See lit.
Indic. as monother. for the maint. tmt. of adult pts. with platinum-sensit. relapsed BRCA-mutated (germline and/or somatic) high grade serous epithel. ovarian, fallop. tube, or primary periton. cancer who are in response (complete response or partial response) to platinum-based chemother.
C/I: Hypersens. Lact. during tmt. and 1 mnth. after the last dose.